REMEGEN (09995.HK) saw its stock price soar by 5.04% in Tuesday's trading session, following two significant announcements that have sparked investor interest. The biotechnology company's shares have been on a remarkable run, with a cumulative increase of over 458% since the beginning of the year.

The primary catalyst for the latest surge appears to be REMEGEN's announcement of a lucrative licensing agreement with Santen Pharmaceutical (China) Co., Ltd., a subsidiary of Japan's Santen Pharmaceutical Co., Ltd. Under the terms of the deal, REMEGEN will grant exclusive rights for its proprietary RC28-E injection in Greater China and several Southeast Asian countries. The agreement includes a non-refundable upfront payment of RMB 250 million, with potential additional payments of up to RMB 1.045 billion in development, regulatory, and sales milestones. Furthermore, REMEGEN will receive tiered royalties on product sales in the licensed regions.

Adding to the positive sentiment, it was reported that a significant shareholder of REMEGEN transferred shares worth HK$784 million from Stock Connect (Shanghai) to HSBC Hong Kong Shanghai Bank. This transfer, representing 4.87% of the company's shares, suggests confidence in the company's prospects and may indicate strategic positioning by major investors. The combination of the licensing deal and the share transfer appears to have bolstered investor confidence, contributing to the stock's impressive intraday performance.